A phase II study by the University of Florida Proton Therapy Institute shows that the use of proton therapy following chemotherapy in 15 patients with Hodgkin lymphoma has a success rate similar to the conventional treatments with a reduction of radiation outside of the target area, potentially reducing the risk of late effects caused by radiation.
An NCI study found that a negative HPV screening test result is a better predictor of low cervical cancer risk than a negative Pap test.
A phase II study of older patients with untreated acute myeloid leukemia showed that treatment with volasertib and low-dose cytarabine more than doubled the objective response rate compared to cytarabine chemotherapy alone.
Somatuline increased progression-free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors in a randomized phase III trial.
An independent data monitoring committee recommended an early stop a phase III trial of Mekinist and Tafinlar in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma, following a demonstrated overall survival benefit.
A phase III trial of trifluridine and tipiracil hydrochloride significantly improved both overall and progression-free survival in refractory metastatic colorectal cancer that had progressed after standard therapies.
ELLEN MILLER SONET was named chief strategy and alliance officer of CancerCare.
JOHN BIRKMEYER was named executive vice president for enterprise support services for the Dartmouth-Hitchcock health system.
KEVIN FITZGERALD, a Jesuit priest, Georgetown bioethicist and cancer researcher, has been appointed by Pope Francis to serve as a consultor to the Pontifical Council for Culture.
V. CRAIG JORDAN will join MD Anderson Cancer Center as a professor in Breast Medical Oncology and Molecular and Cellular Oncology. He will begin work in October.
